EMBO MOL MED 润色咨询

EMBO Molecular Medicine

出版年份:2009 年文章数:1157 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:1.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-02-10 毛大丁

    OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2021-12-28 rayms

    一般期刊要求图表的格式是什么?

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2021-12-29 学医的彭于晏

    什么是三线表?

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2019-03-30 ms4729674192825029

    马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2022-10-06 slientwo

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2022-04-01 143050_0848

    需要上传原始数据吗

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2020-12-31 lovetcm

    EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2019-04-18 sunliang

    钱不是问题,能发就行,单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表:
    OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高

    毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2018-02-26 毛大丁

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章,版面费巨贵,各种抗体什么的还要给验证数据,反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration,后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:EMBO出版社的老三,主要关注临床药物开发,稿子不算多,但是质量还是不错的。拒你同样也很快,EMBO旗下杂志,其实真的很好,不会耽误时间,编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多,几个杂志的分数基本稳定, EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少,所以EMBO杂志比较有影响力,而现在10分以上杂志越来越多,它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题,能发就行,单位的奖励也够版面费了。<span class="quote">毛大丁 2018-02-26 15:37:00 发表:<br>OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高</span>, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:OPEN ACCESS的文章,版面费巨贵,3000欧元,各种抗体什么的还要给验证数据,反正就是很繁琐,反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=430, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=486, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]
    2017-12-06 geneandu

    版面费需要多少啊?

    0

共15条页码: 1/2页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分